CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S87
DOI: 10.1055/s-0038-1640014
Abstracts
Onkologie: Oncology

Role of induction chemotherapy with taxane, cisplatin and 5-fluorouracil in larynx preservation for locally advanced resectable hypopharyngeal cancer: a prospective cohort study

J Fang
1   Beijing Tongren Hospital, CMU, Beijing, China
,
S Liu
1   Beijing Tongren Hospital, CMU, Beijing, China
,
P Li
1   Beijing Tongren Hospital, CMU, Beijing, China
,
S Zhang
1   Beijing Tongren Hospital, CMU, Beijing, China
,
H Ma
1   Beijing Tongren Hospital, CMU, Beijing, China
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction:

    Induction chemotherapy as a larynx preservation treatment strategy is available in advanced hypopharyngeal cancer for over 20 years. We conducted a prospective study to evaluate this protocol with taxene, cisplatin and 5- fluorouracil in China.

    Methods:

    Patients (aged ≥18 years) with untreated, locally advanced hypopharyngeal carcinoma were enrolled from 3 academic medical centers in China. The clinical tumor response was assessed after two cycles of chemotherapy, and patients with a response received a third cycle. Salvage surgery was performed when patients relapsed after chemotherapy and radiation. This study is registered with the Chinese Clinical Trial Registry, number ChiCTR-OOC-17010546.

    Results:

    From January 2012 to December 2015, 176 patients with a median age of 58 years (range, 39 – 80 years) entered the trial. One hundred seven patients (63%) with complete or partial responses to induction chemotherapy received radiotherapy, and 63 patients (37%) with less than a partial response received surgery. The estimated three-year overall survival rate was 44.5% (95% CI 39.5 to 49.5%). There was no difference between responders (44.8%) and non-responders (43.9%) (p = 0.237), however patients who showed a partial response after induction chemotherapy had a significant decrease in survival (32.4%) (p < 0.001).

    Conclusions:

    In patients with hypopharyngeal cancer, induction chemotherapy with TPF regimen followed by radiotherapy for larynx preservation, which is feasible and safe, may be suitable for complete responders but not partial responders.


    #

    No conflict of interest has been declared by the author(s).

    Professor, MD, PhD Jugao Fang
    Beijing Tongren Hospital, CMU,
    No. 8, Chongwenmen Street, Dongcheng District, 100005,
    Beijing,
    China   

    Publication History

    Publication Date:
    18 April 2018 (online)

    © 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York